Noviosense
Phase 2NovioSense has demonstrated the measurement of tear glucose in diabetic patients and the correlation to blood glucose with clinically relevant accuracy. The company announced the commencement of a second, 24-patient study, to validate the use of its tear glucose sensor in type 1 diabetic patients.
Founded
2016
Focus
DiagnosticsMedical Devices
About
NovioSense has demonstrated the measurement of tear glucose in diabetic patients and the correlation to blood glucose with clinically relevant accuracy. The company announced the commencement of a second, 24-patient study, to validate the use of its tear glucose sensor in type 1 diabetic patients.
Funding History
2Total raised: $13.5M
Series A$10MUndisclosedJun 15, 2022
Seed$3.5MUndisclosedJun 15, 2020
Company Info
TypePrivate
Founded2016
LocationEnschede, Netherlands
StagePhase 2
Contact
SIMILAR COMPANIES
2-BBB Medicines
Pre-clinical · Leiden
Batavia Biosciences
Pre-clinical · Leiden
Bilthoven Biologicals
Pre-clinical · Bilthoven
Agendia
Pre-clinical · Amsterdam
Alloksys Life Sciences
Phase 2 · Wageningen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile